BioCentury
ARTICLE | Clinical News

Fosfomycin: Ph II/III ZEUS ongoing

January 24, 2017 2:02 AM UTC

Zavante completed treatment of 465 patients in the double-blind, international Phase II/III ZEUS trial comparing 6 g IV ZTI-01 thrice daily vs. IV piperacillin/tazobactam thrice daily for 7-14 days....

BCIQ Company Profiles

Zavante Therapeutics Inc.